AssetMark’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$193 Sell
16
-17
-52% -$213 ﹤0.01% 3618
2026
Q2
$558 Hold
33
– – ﹤0.01% 3275
2026
Q1
$423 Hold
33
– – ﹤0.01% 3207
2025
Q4
$297 Sell
33
-13
-28% -$179 ﹤0.01% 3198
2025
Q3
$794 Buy
+46
New +$567 ﹤0.01% 2834
2022
Q1
– Sell
-30
Closed -$4K – 1684
2021
Q4
$4K Buy
+30
New +$3.76K ﹤0.01% 1274

Other funds holding NTLA

AssetMark's NTLA Position: Q3 2026 in Review

AssetMark reduced its Intellia Therapeutics (NTLA) stake by 52% in Q3 2026, selling an estimated $213 and leaving 16 shares worth $193. The position accounts for ﹤0.01% of the portfolio, ranked #3618.

AssetMark first reported a position in NTLA in Q4 2021 and has held it in 6 quarters since. The position peaked at $4K in Q4 2021. 239 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • AssetMark held 16 shares of Intellia Therapeutics worth $193 as of Q3 2026.
  • AssetMark sold 17 Intellia Therapeutics shares in Q3 2026, an estimated $213.
  • Intellia Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3618 holding.
  • AssetMark first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • AssetMark's Intellia Therapeutics position peaked at $4K in Q4 2021.
  • 239 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.